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One Sentence Summary: Co-existence of specific IgE and IgG antibodies aggravates NMBA-
induced anaphylaxis in humans 
 
Abstract: 
 
Anaphylaxis is a systemic acute hypersensitivity reaction that is considered to depend on allergen-
specific IgE antibodies, and histamine release by mast cells and basophils. Nevertheless, specific 
IgG have been proposed to contribute when the allergen is a large molecule circulating at a high 
dose, e.g. following therapeutic antibodies or dextran infusions. Data from animal models support 
a (predominant) role for IgG during anaphylaxis to large protein antigens; and a pathway involving 
platelet-activating factor (PAF) release by monocyte/macrophages and neutrophils activated via 
their IgG receptors. We hypothesized that such a pathway may also apply to small drugs and could 
be responsible for non-IgE mediated anaphylaxis and contribute to anaphylaxis severity in humans. 
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We prospectively conducted a multicentric study of 86 patients with suspected anaphylaxis to 
neuromuscular-blocking agents (NMBA) during general anesthesia and 86 matched controls. We 
found that concentrations of anti-NMBA IgG and markers of IgG receptor activation, PAF release 
and neutrophil activation correlated with anaphylaxis severity. Neutrophils underwent 
degranulation and netosis early after anaphylaxis onset, and plasma-purified anti-NMBA IgG 
triggered neutrophil activation ex vivo in the presence of NMBA. Importantly, neutrophil 
activation could also be observed in patients lacking evidence of classical IgE-dependent 
anaphylaxis. This study supports the existence of an IgG-neutrophil-PAF pathway in human 
NMBA-induced anaphylaxis, which may aggravate anaphylaxis in combination with the IgE-
pathway or underlie anaphylaxis in the absence of specific IgE. These results reconcile clinical 
and experimental data on the role of antibody classes in anaphylaxis, and should inform diagnostic 
approaches to NMBA-induced acute hypersensitivity reactions.  
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 [Main Text: ] 
 
Introduction 
 
 Anaphylaxis is an immune-mediated systemic acute hypersensitivity reaction (AHR) 
occurring rapidly upon contact with an allergen in sensitized individuals. Clinical signs include 
bronchoconstriction, severe vasodilatation and hypovolemia that can lead to multi-organ 
dysfunction and death. The most prominent cause of anaphylaxis in adult is drugs, notably 
antibiotics and neuromuscular blocking agents (NMBA). Anaphylaxis is classically considered to 
rely on IgE antibodies against the allergen/antigen, and to involve massive histamine liberation by 
mast cells and basophils, following antigen-induced aggregation of IgE receptor (FcεRI)-bound 
specific IgE antibodies (1). The clinical diagnosis of anaphylaxis to NMBA is based on this IgE 
paradigm. Surprisingly, to 10-20% of patients who experience an AHR consistent with an 
anaphylactic reaction do not present with any biological signs of IgE-dependent immune activation 
(positive skin test, presence of specific IgE, elevated histamine or tryptase concentrations) (2, 3), 
suggestive of other potential mechanisms. Among these, IgG antibodies have been proposed to 
trigger IgE-independent anaphylaxis induced by some protein antigens or large molecules (e.g. 
therapeutic antibodies, protamine, dextran) (3-9), but the underlying pathological mechanism 
remains however largely unknown. Furthermore, there is a lack of understanding of why for some 
patients the severity of the AHR varies widely, despite similar degrees of activation of the IgE 
pathway.  
 Supporting a paradigm of non IgE-dependent pathways of anaphylaxis, mouse studies have 
demonstrated that anaphylactic reactions may occur in the absence of IgE (10), IgE receptors (11, 
12) or mast cells (12, 13). Antibodies of the IgG class are often responsible for these non-IgE 
reactions, via the generation of IgG-antigen/allergen immune complexes (ICs). These complexes 
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engage IgG receptors (FcγR) on various myeloid cells (14-16), including monocytes/macrophages 
(17, 18) or neutrophils (19), but also basophils (20) or mast cells (12), depending on the model of 
anaphylaxis used. FcεRI or FcγR engagement leads to internalization and downregulation of these 
receptors (21), which has been proposed as means to distinguish types of anaphylaxis, i.e. FcεRI 
downregulation on mast cells and basophils as a marker of IgE-induced anaphylaxis (22) and FcγR 
downregulation on neutrophils and/or monocytes as a marker of IgG-induced anaphylaxis (23, 24). 
Our previous work showed that neutrophils play a dominant pathogenic role in mouse models of 
severe anaphylaxis (19); including models driven by human IgG and human IgG receptors (24, 
25), suggesting that neutrophils could also contribute to anaphylaxis in humans. Neutrophils may 
even be sufficient to induce anaphylactic symptoms, as they can rapidly release a number of potent 
lipid and protein mediators upon activation, and can also extrude their genomic and mitochondrial 
DNA decorated by potent enzymes in the form of Neutrophil Extracellular Traps (NETs) - a 
process termed netosis (26). Neutrophils are major producers of platelet-activating factor (PAF) 
(27, 28) and release PAF in vitro upon FcγR triggering (19, 25), which also implicates these cells 
in anaphylaxis pathogenesis. Indeed, IgG-dependent experimental anaphylaxis in animal models 
has been repeatedly reported to rely on PAF as a mediator, alone or in combination with histamine 
(15, 19, 20, 24, 29, 30). Importantly, elevated PAF concentrations can be detected in the serum of 
human patients following anaphylaxis and correlate with reaction severity (31, 32). 
 To investigate the putative contribution of an “IgG antibody - neutrophil - PAF“ pathway 
to human anaphylaxis to small drug molecules, we performed a first-in-kind prospective 
multicentric study on patients with suspected NMBA-induced AHR during anesthesia. We found 
that neutrophils were activated early after anaphylaxis onset and underwent degranulation as well 
as netosis. Anti-NMBA specific IgG concentrations, neutrophil activation markers, IgG receptor 
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downregulation and PAF-acetylhydrolase (PAF-AH) activity were associated with anaphylaxis 
severity. Importantly, neutrophil activation was observed in patients for whom evidence of 
classical IgE-dependent anaphylaxis was lacking. Finally, plasma-purified anti-NMBA IgG 
antibodies triggered neutrophil activation and netosis ex vivo in the presence of NMBA. A 
pathogenic IgG-neutrophil-PAF pathway may thus underlie severe drug-induced anaphylactic 
events in humans. 
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[ Results : ] 
 
  
 
Anti-NMBA specific IgE and IgG concentrations associate with anaphylaxis severity 
 Due to the unpredictability and low-incidence of anaphylactic events to NMBA (1 out of 
10,000 anesthesia procedures), we prospectively recruited a multicentric cohort of patients with 
acute hypersensitivity reactions to NMBA injection, along with matched controls (Tables 1-2; 
additional parameters of the cohort described in reference (33)). Reaction severity was 
retrospectively classified as mild (grade 1 and 2) or severe (grade 3 and 4) according to Ring and 
Messmer classification. Patients (n=86) received suxamethonium (n=39), atracurium (n=35), 
rocuronium (n=3) or a mixture of atracurium and suxamethonium (n=9) (Fig.1b-d; Table S1). 
Among those the frequency of severe (grade 3/4) AHR was 72%, 37%, 33% and 22%, respectively, 
indicating that severe reactions can occur in response to any of the NMBA used. 
 All NMBA contain quaternary ammonium groups, which are considered the main 
antigenic epitope. Circulating anti-NMBA antibodies were quantified using the quaternary 
ammonium morphine compound (QAM; Fig.1a) as a surrogate molecule: thereby antibodies 
against this shared epitope were detected as serum anti-QAM IgE and anti-QAM IgG. As expected 
(34), anti-QAM IgE were elevated in patients with AHR compared to controls (P<0.0001), but 
were also higher in patients with reactions graded as severe versus mild (P<0.0001) (Fig.1d; Table 
S1). Anti-QAM IgE are considered the most sensitive biomarker in NMBA-anaphylaxis (35), and 
were not detected in 98% of controls, yet surprisingly were also undetectable in 72% of patients 
with anaphylaxis. Conversely, circulating anti-QAM IgG were detected in all controls and patients, 
but nevertheless were found at significantly higher concentrations in patients with severe AHR 
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compared to mild (P<0.0001), or to controls (P=0.007) (Fig.1e). Patients with very low 
(<0.5µg/mL) anti-QAM IgG had undetectable anti-QAM IgE (Fig.1f). Detectable anti-QAM IgE 
concentrations correlated significantly with anti-QAM IgG (P=0.0009, Fig.1f, inset), indicating 
that whenever a patient had high anti-QAM IgE they also had high anti-QAM-specific IgG. 
Importantly, the reverse was not true, as several patients had anti-QAM specific IgG without 
detectable IgE. Irrespective of reaction severity, patients presenting with the highest anti-QAM 
IgE or IgG concentrations also tended to present with high anti-NMBA-specific IgE and IgG, 
detected via both clinically-validated and research-grade ImmunoCAP assays (Fig. S1). Thus, both 
anti-QAM IgE and IgG concentrations correlated with NMBA-induced anaphylaxis severity. 
 
IgG receptor downregulation on neutrophils is associated with anaphylaxis severity 
 The presence of elevated concentrations of circulating anti-QAM IgE and IgG in patients 
with severe AHR suggests that upon intravenous injection, NMBA may immediately interact with 
anti-NMBA IgE-sensitized cells in circulation and that ICs of [anti-NMBA IgG – NMBA] may 
instantaneously form to engage FcγRs on myeloid cells. Our analyses revealed significantly lower 
FcεRI expression on basophils, but not on eosinophils, from patients during severe AHR compared 
to their baseline expression measured during the follow-up visit (V2) or compared to controls 
(Fig.2a,b; P=0.02 and P=0.01, respectively). Among IgG receptors (Fig.2c-l), CD32A and CD16, 
but not CD64, demonstrated lower expression on neutrophils from severe AHR patients during 
AHR compared to controls (Fig.2e,k). Importantly, this reduction was also apparent compared to 
baseline expression measured during the follow-up visit (V2), indicating that these IgG receptors 
are not constitutively downregulated in these patients. Downregulation of CD32A and CD16 on 
neutrophils was significantly more pronounced in patients with severe versus mild reactions 
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(P<0.0001 and P=0.0004, respectively). Monocytes from patients with severe AHR also 
demonstrated modest CD32A downregulation compared to controls, but no modulation of CD64, 
CD16 or of the inhibitory IgG receptor CD32B (Fig.2d,h,j,l). Basophils showed a tendency 
towards reduction of CD32B during severe AHR compared to baseline expression (V2), mild AHR 
patients or controls (Fig.2i). When we performed similar analyses after segregating patients 
according to the NMBA administered, we confirmed a downregulation of CD32A and CD16 on 
neutrophils and CD32A on monocytes during suxamethonium-induced AHR, and of CD32A on 
neutrophils during atracurium-induced AHR (Fig. S2a-d). Of note, there were too few rocuronium-
induced severe AHR cases to permit statistical comparisons in this particular subgroup.  
Altogether, these data reveal downregulation of specific activating IgG receptors on neutrophils 
and monocytes in patients with severe AHR. These data are consistent with the hypothesis that 
FcγR are engaged by circulating IgG-ICs following NMBA injection in AHR patients. Further 
supporting this hypothesis, concentrations of complement components C3 and C4, and 
complement activity (50% hemolytic activity, CH50) were significantly reduced during severe 
AHR compared to baseline (V2) (P<0.0001, Fig. S3), suggesting activation of the classical 
complement pathway by IgG-ICs during severe NMBA-anaphylaxis. 
Neutrophils are activated during human anaphylaxis 
 Downregulation of activating IgG receptors during AHR was predominant on neutrophils 
compared to other myeloid cells (Fig.2). We therefore investigated the activation status of 
neutrophils during AHR by measuring surface markers CD11b, CD18 and CD66b, circulating 
neutrophil elastase, DNA-myeloperoxidase complexes (DNA-MPO) as a measure of circulating 
NETs and PAF-acetylhydrolase (PAF-AH) activity, as an indirect measure of PAF concentrations. 
Expression of CD11b, CD18 and CD66b were all significantly increased on neutrophils from 
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patients with severe AHR compared to controls (P=0.0003, P=0.001, and P=0.02, respectively; 
Fig.3a-c). Neutrophil elastase was significantly increased in the plasma during severe AHR 
compared to controls, or to baseline (V2) concentrations (P<0.0001 for both, Fig.3d). DNA-MPO 
complexes detected in the serum, were also significantly increased in severe AHR compared to 
controls (P<0.0001) or patients with mild AHR (P<0.0001, Fig.3e). PAF-AH activity was 
significantly lower in patients with severe AHR compared to controls or mild AHR (P<0.0001 and 
P=0.01, respectively, Fig.3f), which is indicative of elevated plasma PAF concentrations. 
Interestingly, expression of both CD11b and CD18, and circulating concentrations of DNA-MPO 
complexes, were also significantly higher in patients with mild AHR compared to controls 
(P=0.004, P=0.007 and P=0.001) indicating that evidence of an IgG pathway of immune activation 
is not only associated with severe AHR (Fig.3a,b,e). Moreover, CD11b, CD18 and DNA-MPO 
remained elevated in severe AHR patients even 6-8 weeks after the reaction (V2, Fig.3a,b,e). 
Similar analyses after separating patients according to the NMBA used supports and sustained 
upregulation of CD11b and CD18 on neutrophils and NET release during and after 
suxamethonium-induced severe AHR (Fig. S2e,f). To ascertain that the link between neutrophil 
activation and anaphylaxis severity was not biased by treatments given during AHR (epinephrine, 
fluids, or other drugs), we incubated neutrophils from healthy donors with a wide range of 
concentrations of these compounds in vitro and assessed neutrophil activation, or capacity to be 
activated by standard stimuli. Epinephrine, ephedrine, atropine and resuscitation fluids had no 
effect on neutrophil activation. Only methylprednisolone at concentrations far above therapeutic 
range could induce a weak neutrophil activation as measured by NET release (Fig. S4). Of note, 
no correlation between corticosteroid administration (in 20/86 patients) and serum NET 
concentrations or AHR severity could be identified in the cohort. Altogether these data provide 
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evidence of neutrophil activation in patients with intra-anesthetic AHR and demonstrate that the 
degree of neutrophil activation associates with AHR severity. 
 
IgG-dependent neutrophil activation can occur concomitantly with, or independently of IgE-
mediated anaphylaxis 
 Patients experiencing severe AHR had higher anti-QAM IgE and decreased FcεRI 
expression on basophils compared to controls (Fig.1-2), as well as elevated histamine and tryptase 
concentrations (Table S2). The same patients also had higher anti-QAM IgG concentration, 
decreased FcγR expression and greater evidence of neutrophil activation and degranulation (Fig.1-
3) compared to controls. Patients with severe AHR thus presented markers typical of both IgE- 
and IgG-dependent anaphylaxis. To assess if an IgG-dependent pathway could exist independently 
of the IgE-dependent pathway, we evaluated the presence of IgG-pathway markers relative to the 
likelihood of IgE-dependent activation. To this end, evidence for an IgE-dependent anaphylactic 
reaction was classified as “absent” (n=27, 31%), “equivocal”(n=19, 22%) or “strong” (n=40, 47%) 
for each patient based on clinical data, skin tests and biological tests used in standard care, by a 
consortium of experts blinded to the IgG status of the patients (33) (see Methods). Only the 
“strong” patient subgroup presented significantly reduced FcεRI expression on basophils, 
compared to controls, “absent” or “equivocal” groups (Fig.4a, P=0.001, P=0.003 and P=0.01, 
respectively). The “strong” patient group had higher anti-NMBA IgG (Fig.4b), lower CD32B 
expression on basophils (Fig.4c), lower CD32A expression on monocytes (Fig.4d), lower CD32A 
and CD16 expression on neutrophils (Fig.4e-f) and higher circulating elastase and DNA-MPO 
complexes concentrations (Fig.4g-h), compared to controls. This group also showed higher 
CD11b, CD18 and CD66b expression on neutrophils (Fig.4i-k) and lower PAF-AH activity 
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(Fig.4l). Furthermore, the “strong” patient group also had significantly higher anti-NMBA IgG, 
elastase and NET release, and lower CD32A and CD16 expression on neutrophils than the “absent” 
group (Fig.4b,e-h, P=0.0001, P=0.02, P=0.03, P=0.005 and P=0.02, respectively). Additionally, 
patients in the “strong” group presenting with severe AHR had higher anti-NMBA IgG (P=0.003), 
circulating NETs (P=0.004), neutrophil CD11b expression (P=0.03) and lower neutrophil CD32A 
expression (P=0.0009) than those with mild AHR (Fig. S5). These results substantiate the co-
existence of IgE- and IgG-dependent mechanisms in AHR patients with strong evidence of IgE-
dependent anaphylaxis, suggesting that both pathways may contribute to AHR induction and 
severity. Moreover, the “absent” group, which would usually be categorized as idiopathic in 
standard care had significantly more circulating NETs, higher expression of CD11b, CD18 (all 
P<0.01), and a trend towards lower neutrophil CD32A expression (P=0.07) but no difference in 
FcεRI expression compared to the control group (Fig.4a,e,h-k). Thus, we document neutrophil 
activation during NMBA-induced AHR in patients for whom evidence of an IgE-dependent 
pathway is lacking despite clinical signs compatible with anaphylaxis. These results substantiate 
the existence of an autonomous IgG-dependent mechanism that could lead to severe reactions, 
since 26% of patients in the “absent” group developed severe AHR. An IgG-, FcγR-, neutrophil- 
pathway may therefore be responsible for NMBA-induced AHR in these patients, provided that 
anti-NMBA IgG ICs are, indeed, able to trigger neutrophil activation. 
 
Patient-derived anti-NMBA IgG activate neutrophils ex vivo in the presence of NMBA 
 Immune complexes formed by specific antibodies binding directly to small chemical 
entities such as NMBA (with molecular weights of 290, 530 and 929 Da for suxamethonium, 
rocuronium and atracurium, respectively) are not expected by themselves to be sufficiently large 
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or multivalent to activate cells through FcR triggering. Rather, larger molecules such as serum 
proteins may serve as substrates for NMBA haptenization, but the precise in vivo chemistry 
remains unknown (36). Indeed, it has been reported that the free fraction of suxamethonium and 
rocuronium are reduced to 80% and 54% after infusion (37). We therefore investigated the 
potential interaction of these NMBA with abundant human serum proteins using microscale 
thermophoresis. Rocuronium, but not suxamethonium, was found to interact with human serum 
albumin (HSA, a known carrier of basic compounds), orosomucoid (a known carrier of acidic and 
neutral compounds) and transferrin, but not with human IgG1 (Fig. S6a-d). The affinity of all these 
interactions was very poor, however, necessitating NMBA concentrations in the range of 1-4mM 
(Fig. S6e-h), suggesting that at standard intubation doses of rocuronium (0.6-1.2mg/kg, estimated 
to correspond to ~18-36µM in circulation), other molecules may be the partners for NMBA 
haptenization. 
In the absence of an identified protein partner in human serum for rocuronium 
haptenization, we developed a set of tools, including purified human anti-rocuronium antibodies, 
rocuronium and succinylmonocholine-albumin bioconjugates and an anti-rocuronium ELISA, to 
investigate the potential for anti-NMBA IgG ICs to activate FcγR-expressing neutrophils. Anti-
rocuronium IgG ELISA permitted the identification of 4 patients with high serum concentrations 
of rocuronium-specific antibodies (Fig.5a), of whom one patient (#7016; mild AHR following 
atracurium administration – refer to Table S1) consented for additional blood sampling. Anti-
rocuronium IgG purified from this patient’s plasma (Fig.S7a) was confirmed to bind to 
rocuronium, and also cross-reacted with some other ammonium-containing molecules by ELISA, 
i.e. morphine antigen- and suxamethonium-bioconjugates, but not other NMBAs or unrelated 
antigens or allergens (Fig.5b). In addition, binding of these purified IgGs could be dose-
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dependently inhibited using free rocuronium or suxamethonium in solution, but not by the 
rocuronium-analog molecule 5-α-dihydrotestosterone (5aDHT) that lacks quaternary ammonium 
groups, nor by atracurium, cis-atracurium, pancuronium or vecuronium (Fig. S7b). This confirms 
a binding preference of these purified IgG to rocuronium and suxamethonium, but no cross-
reactivity to the other four NMBA tested. Purified anti-rocuronium IgG could form ICs with 
rocuronium-bioconjugate, and bind to cell transfectants expressing CD16A (Fig.5c). Finally, 
human neutrophils from healthy controls produced reactive oxygen species (ROS) and released 
NETs when incubated on plate-bound rocuronium ICs (Fig.5d,e); moreover, they upregulated 
CD11b and CD66b expression and produced ROS when incubated with soluble rocuronium ICs 
(Fig. S8). Thus, anti-rocuronium IgG isolated from AHR patients can directly activate human 
neutrophils in the presence of the culprit NMBA. 
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Discussion  
 
 This study provides several converging lines of evidence for the contribution of an IgG-
FcγR-neutrophil-dependent pathway to human anaphylaxis, using NMBA-induced AHR as a case 
study. Such a pathophysiological mechanism entails the presence of IgG antibodies against NMBA 
in patients, leading, together with administered NMBA, to the formation of immune complexes 
that primarily engage two activating IgG receptors on neutrophils, CD32A/FcγRIIA and 
CD16B/FcγRIIIB. Consequently, neutrophils become activated as shown by increased expression 
of activation markers, degranulation of neutrophil elastase, and elevated circulating NETs. 
Presumably, such an IgG-dependent pathway leads to the release of the highly potent lipid 
mediator PAF. It may worsen AHR in concert with IgE-dependent immune activation, or could 
even be responsible for AHR induction in the absence of IgE-mediated reactions. 
 Anaphylaxis induction by pathogenic IgG rather than IgE antibodies has been 
demonstrated by many groups in animal models (15, 17, 20). Moreover, IgG has been implicated 
in rare clinical studies on anaphylaxis induced by high molecular weight or protein antigens, such 
as therapeutic antibodies, dextran, protamine or von Willebrand factor (3-8, 38). Indeed, patients 
with elevated anti-infliximab or anti-protamine IgG antibody concentrations have a greater risk to 
develop anaphylaxis during treatment (7, 8, 39), suggesting a direct role for IgG in anaphylaxis 
pathogenesis. This study is, however, the first report of a potential IgG pathway in human 
anaphylaxis caused by a low molecular weight (<1kDa) antigen, i.e. NMBAs. Interestingly, the 
commonality between previous clinical studies and the current report is that the culprit antigen is 
administered intravenously in rather large quantities, favoring the formation of ICs in circulation. 
Our study reports low affinity interactions between rocuronium and prominent human plasma 
proteins (HSA, orosomucoid, transferrin); yet these mM range interactions cannot explain 
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interactions that form when NMBA circulate at µM concentrations in patients’ plasma. Hence the 
in vivo haptenization chemistry of NMBA remains unknown, along with the identity of putative 
carrier molecule(s) that may enable NMBA-IgG immune complexes to form and activate FcγR-
expressing myeloid cells. 
Thirty-one percent of AHR patients in our study lacked biomarkers of IgE-dependent 
anaphylaxis, of which 26% had severe reactions: these data corroborate the existence of 
alternative, IgE-independent pathways of NMBA-anaphylaxis. An entirely different, and 
antibody-independent, pathway of anaphylaxis has been reported following cationic drug 
administration, involving an interaction with Mas-related G-protein coupled Receptor X2 
(MRGPRX2) on mast cells (40, 41). Nevertheless, such a phenomenon cannot explain the “non-
IgE” reactions we observed: among the three culprit NMBAs in our study, only atracurium and 
rocuronium, but not suxamethonium, could potentially induce such a response and, if so, would 
result in positivity for some IgE-dependent biomarkers, such as elevated histamine concentrations 
and positive skin tests (41). 
 Surprisingly, concentrations of anti-QAM IgG were similar between the AHR population 
and the controls, although severe AHR patients had higher anti-QAM IgG than mild AHR patients. 
The latter observation is in line with the principle of dose/concentration-dependent formation of 
ICs, and may contribute to AHR severity. As quaternary ammonium groups and similar moieties 
are present in a large number of household products, hair colorations and anti-cough medication 
(42), generalized positivity for anti-QAM IgG likely reflects exposure of the general population to 
these compounds. It remains unclear, however, why controls with high anti-QAM IgG do not 
develop AHR following NMBA infusion. Anti-QAM IgG antibodies could have different affinities 
in patients versus controls, which could affect both their capacity to form ICs in the presence of 
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NMBA, and to compete with IgE for NMBA binding (43). Supporting this notion, this cohort 
demonstrates a positive correlation between high concentrations of anti-QAM IgE and IgG, both 
in patients and in the rare controls with positive anti-QAM IgE. Using a combination of clinically 
validated tests, and research assays not yet validated for clinical practice, our analyses revealed 
that specific IgE concentrations for suxamethonium, atracurium and rocuronium also tended to be 
higher in samples initially determined as high for anti-QAM IgE. This may also be the case for 
IgG, particularly for suxamethonium-specific IgG, even if no threshold of “positivity” for anti-
NMBA IgG has ever been established (Fig. S1). 
 Neutrophils from severe AHR patients early after reaction onset demonstrated increased 
expression of activation markers CD18, CD11b and CD66b compared to mild AHR patients. These 
data reveal, for the first time, the activation of neutrophils during NMBA-induced AHR in humans, 
and correlate the severity of AHR with elevated neutrophil-specific circulating markers: elastase 
and NETs. A role for neutrophils in anaphylaxis has previously been reported in animal models 
(19, 44-46). Circulating NETs and expression of CD11b and CD18 were also higher in mild AHR 
patients than controls, perhaps indicating that these are more sensitive markers of neutrophil 
activation than circulating elastase or CD66b expression. Considering patients subgroups 
according to the NMBA received, an increase of CD18 and CD11b on neutrophils remained highly 
significant when examining suxamethonium-infused patients, but was less apparent in atracurium-
infused patients. Antibody-independent alternative mechanisms reported for AHR induction by 
atracurium (47) may be confounding factors in the latter analysis. Two key findings strongly 
suggest the direct activation of neutrophils as a consequence of their interaction with NMBA-IgG 
ICs. First, the downregulation of FcγR CD32A and CD16B on neutrophils from AHR patients, 
and second the in vitro demonstration that NMBA-IgG ICs induce neutrophils to produce ROS 
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and NETs. Less pronounced CD32A downregulation on monocytes from severe AHR patients 
suggests concomitant monocyte activation directly by NMBA-IgG complexes, of lesser 
magnitude, which may also contribute to mediator release and AHR induction/severity. Indeed, 
stimulation of neutrophils and monocytes from CD32A transgenic mice via CD32A results in the 
production of PAF and other lipid mediators (25) and more generally, engagement of CD32A by 
IgG-ICs results in activation of cells in vitro and in vivo (48, 49), including NET release (50). 
When analyzing suxamethonium-infused or atracurium-infused patients, only the downregulation 
of CD32A on neutrophils remained highly significant (Fig. S2). Altogether, these findings suggest 
CD32A as a marker for IgG-dependent severe AHR, at least those induced by suxamethonium and 
atracurium. 
 The relative contribution of cell subsets to anaphylaxis has been described using depletion 
studies in mouse models (15, 17, 19, 51), and is highly dependent on the model used (23, 52, 53). 
Our previous reports using a mouse model expressing human FcγRs (CD32A, CD32B, CD16A, 
CD16B) in place of mouse FcγRs showed neutrophils to be predominant (24) whereas using mice 
expressing only human CD32A showed neutrophils and monocytes to contribute equally (25). The 
very high co-expression of CD16B with CD32A on neutrophils may favor neutrophil activation 
over monocytes during the induction phase of anaphylaxis, and explain both the results obtained 
in mice (24) and the clinical results presented herein. IgG-dependent pathways may thus 
preferentially trigger neutrophils whereas IgE-dependent pathways may preferentially trigger mast 
cells (9, 54). The main anaphylactogenic mediators reported for these two modalities are PAF (19, 
20) and histamine (30, 55), respectively. Even though neutrophils represent by far the largest cell 
population in circulation and a major source of PAF, most cell subsets that have been proposed to 
contribute to anaphylaxis can produce PAF, including IgG-IC stimulated monocytes and basophils, 
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and IgE-stimulated mast cells (56-58). The reduction in PAF-AH activity we observed in severe 
AHR patients indirectly substantiates elevated PAF concentrations during NMBA-AHR. In 
addition, we observed consumption of complement components during severe AHR, suggesting 
that complement may also contribute to the severity of anaphylaxis (59-61) by potentiating 
myeloid cell activation, in conjunction with PAF, histamine and other mediators. This first 
observation needs however to be confirmed in additional studies as a complement consumption 
could be also a consequence of general anesthesia (62). 
 Circulating DNA-MPO complexes are markers of NETs and here we identify that their 
concentrations in circulation are associated with AHR severity. While NETs have been implicated 
in some allergic contexts, such as asthma (63), this is the first report to describe netosis in 
anaphylaxis. NETs may contribute to AHR directly, by toxic effects of their components on tissues 
and epithelia (64), thereby impeding organ function. Alternatively, the involvement of NETs in 
AHR may be via activation of the coagulation contact system (65), which has been linked to the 
severity of anaphylaxis (66). Elevated amounts of circulating NETs were detected in patients 
during the acute phase of AHR and remained even 6-8 weeks later, whether considering all patients 
or subgroups infused with suxamethonium only or with atracurium only. The maintenance of 
elevated NET concentrations long after clinical remission could represent a biomarker of persistent 
inflammation after the initial systemic reaction. Not only NET concentrations but also expression 
of neutrophil activation markers (CD11b, CD18) were elevated in patients at the time of the follow-
up visit 6-8 weeks post-AHR, a finding which was also significant when analyzing only patients 
infused with suxamethonium. Such a long-lasting effect of AHR on neutrophil activation status is 
in accordance with one study, which found elevated transcription of neutrophil-related genes in 
patients with a previous episode of anaphylaxis (67). 
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Our study carries some limitations due to the design and observational nature. First, we 
report here a consistent correlation between several IgG-dependent markers and anaphylaxis 
severity, but we cannot prove direct causality between neutrophil activation and anaphylaxis. 
Second, basophils from severe AHR patients demonstrated significantly lower IgE receptor 
(FceRI) expression during the anaphylaxis event than during the allergology visit 6-8 weeks post-
AHR. Whereas fast downregulation of FceRI after IgE-allergen triggering has been reported on 
rat and mouse mast cells (68), reports do not support the existence of such a consequence on human 
basophils (69, 70). This discrepancy might relate to a different behavior of human basophils in 
vivo than in vitro, to the nature of allergen aggregating the IgE-FceRI complex, to FcgRs dragging 
IgE-bound FceRI inside the basophil after interaction with IgG-allergen complexes, or even an 
unknown bystander effect of anaphylaxis. Third, although we classified our patients according to 
the likelihood of an IgE-dependent reaction, we did not account for other reactions, e.g. 
pharmacological activation of mast cells (41) or non-specific histamine release (71), which can 
represent alternative mechanisms of anaphylaxis induction in the absence of specific IgE. 
In conclusion, this work defines a clinically-relevant pathway of NMBA-induced AHR, 
involving IgG, IgG-receptors and neutrophils. This pathway may co-exist with the classical IgE-
dependent pathway, and compound the severity of IgE-associated “allergic” AHR. It could also be 
responsible for AHR in patients with no markers of IgE-dependent immune activation; previously 
designated “non-allergic” AHR (72). Furthermore, in patients showing strong evidence for 
engagement of the IgE-dependent pathway, IgG markers remained strongly associated with 
anaphylaxis severity, indicating that simultaneous engagement of IgG- and IgE-dependent 
mechanisms may occur during human anaphylaxis. Our data suggest that these pathways can 
combine to worsen AHR. We predict that our findings can be extrapolated to most AHR wherein 
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the culprit allergen(s) are present in the circulation. Evaluation of specific IgG markers in the 
clinical AHR diagnostic process may clarify diagnosis and be a way to risk-stratify patients. Our 
results also pave the way for novel therapeutic interventions, particularly aiming at IgG receptor 
blockade. 
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[ Materials and Methods : ] 
 
Study design 
The multicentric NASA (“Neutrophil Activation in Systemic Anaphylaxis”) study involved 11 
Anaesthesia and Intensive Care departments in the Ile-de-France region in France 
(https://clinicaltrials.gov/ct2/show/NCT01637220). The study was approved for all centers by an 
Institutional Review Board (ethical committee “Comité de Protection des Personnes Ile-de-France 
1", reference 2012-avril-12880), and registered before the first inclusion at ClinicalTrials.gov 
(Identifier: NCT0163722). The design of the study and detailed clinical characteristics of the 
patients are described elsewhere (33). Briefly, patients with clinical signs consistent with intra-
anaesthetic AHR to NMBA were prospectively included between November 2012 and June 2014. 
Venous blood samples were collected at 30 minutes and 2 hours following the onset of the AHR 
and during the allergology-anaesthesia visit 6-8 weeks post-AHR. At this visit, immediate reading 
intra-dermal tests against suspected culprit agents were performed. Clinical, biological and 
demographic patient data are summarized in Tables 1 and 2. Patients were classified a posteriori 
in grades of severity according to the Ring and Messmer classification (73) by two independent 
intensive care unit experts. A severe AHR was defined as a grade 3 or 4 (severe organ failure or 
cardiac/respiratory arrest) while a mild AHR was defined as a grade 1 or 2. Classifications of AHR 
according to evidence of an IgE-mediated pathway, i.e. “strong”, “equivocal” or “absent”, were 
established a posteriori by a consortium of six experts taking in account clinical symptoms, 
tryptase, histamine, specific IgE and results of skin tests. For each patient included, a control was 
recruited: a patient undergoing surgery with NMBA without any signs consistent with intra-
anaesthetic AHR. Controls were matched to patients for age (± 5 years), sex, NMBA used, type of 
surgical procedure and infectious status. Written informed consent was obtained from the patients 
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or their legal representative before study inclusion. By French law, in case of impaired decision-
making capacity without a legal representative available at the time of inclusion, the patient’s 
informed consent could be obtained after enrollment (“emergency inclusion”). Venous blood 
samples were collected 30 minutes after anesthesia for controls. 
Classical anaphylaxis parameters 
As part of standard care procedures, the following circulating parameters were assessed as 
previously described (35): histamine (EIA, Immunotech, Beckman Coulter, Brea, California, 
USA) and tryptase (FEIA, ImmunoCAP 250 Phadia, Thermofisher®, Waltham, Massachusetts, 
USA) in plasma and anti-quaternary ammonium-specific IgE (FEIA, ImmunoCAP 250 Phadia, 
Thermofisher®, Waltham, Massachusetts, USA) in serum. A value less than 0.35kU/L of specific 
IgE was considered negative, as recommended (35). Tryptase concentrations two hours following 
AHR were considered elevated when greater than (1.2 x [baseline tryptase] + 2 µg.L-1) as recently 
recommended (74). A histamine concentration above 20 nmol.L-1 30 minutes following AHR was 
considered elevated. Data is summarized in Table S2. 
In addition, specific IgE concentrations for suxamethonium were assessed using the clinically-
validated suxamethonium ImmunoCAP (Phadia ImmunCAP#c202). Moderately sensitive 
ImmunoCAPs for atracurium (75) and rocuronium (76) were obtained as experimental prototypes 
made for research use (Phadia AB, Uppsala, Sweden). Of note atracurium ImmunoCAP is 
prepared using tetrahydropapaverine modified with b-propiolactone, as a surrogate for atracurium, 
before conjugation to poly L-lysine (atracurium ImmunoCAP conjugate) (77). 
To avoid commonly reported problems with the diagnosis of IgE-dependent reactions (false 
negative tryptase/histamine measurements), blood sampling was carefully and uniformly 
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performed across the study and there was no difference in delay before blood sampling between 
patients with a negative or a positive plasma tryptase (Table 2). Specific IgE were analyzed on a 
unique instrument, and skin tests performed and analyzed by only three allergologists. 
Complement measurements 
Complement haemolysis 50% (CH50) activity and complement fractions C3 and C4 were 
determined by turbidimetry on a SPA + analyzer (Binding Site, Birmingham, UK) according to 
the manufacturer's instructions and standard practice of the laboratory. 
Human plasma protein interactions with NMBA 
Protein binding of NMBA was studied by microscale thermophoresis (MST) measurements on a 
Monolith LabelFree (NanoTemper, Gmbh). Rocuronium pre-dilutions were prepared by 16-fold 
2:1 serial dilutions of compound in PBS buffer to yield a range of 8mM to 18µM in a final volume 
of 10µL. Lower concentrations were studied in preliminary experiments and did not show any 
binding. Rocuronium dilutions were mixed with 10µL of target proteins (human serum albumin 
(HSA), transferrin, orosomucoid and IgG1), at 2µM final each. Samples were loaded in standard 
treated capillaries (NanoTemper, LLC, Munich, Germany). Experiments were performed with 
MST power medium (20%) and LED intensity of 10 or 20%. Each experiment was performed in 
duplicate and reproduced 3 times. Data was analyzed using MO Affinity Analysis software 
(NanoTemper Technologies). 
 
 
Specific IgG measurement 
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Anti-QAM IgG concentrations were measured using an adaptation of the ImmunoCAP® matrix 
used to measure anti-QAM IgE concentrations (considered the most sensitive marker for IgE-
induced NMBA-AHR(35)) (Phadia, Thermofischer, Waltham, Massachusetts, USA). As no 
reference interval exists for this parameter, raw values were evaluated relative to an IgG calibration 
curve and expressed in µg/mL. The secondary antibody used to detect IgG in the ImmunoCAP is 
a mouse monoclonal IgG1 antibody binding all four human IgG subclasses (Phadia). The human 
IgE detection reagent was replaced with the same monoclonal anti-human IgG reagent in the 
clinically-validated suxamethonium ImmunoCAP (Phadia ImmunCAP c202), or research-grade 
atracurium ImmunoCAP and rocuronium ImmunoCAP (Phadia AB, Uppsala, Sweden) to detect 
anti-suxamethonium, -atracurium or -rocuronium IgG, respectively. 
Flow cytometric analysis of Fc receptors and activation markers 
Heparinized blood sampled during NMBA-induced AHR and at the patient’s allergy visit, as well 
as blood from anesthetized matched controls, was immediately transported from the site of blood 
collection to the Institut Pasteur (Paris, France). Upon receipt, RBC were lysed using ACK buffer, 
white blood cells washed in PBS/1% Bovine Serum Albumin (BSA) / 2 mM EDTA and incubated 
with indicated antibodies for 30 min at 4°C (Table S3). Cells were washed and acquired on a 
MACSQuant flow cytometer (Miltenyi Biotech®, Bergisch Gladbach, Germany) and analyzed 
using FlowJo software (Treestar, Ashland, Oregon, USA). Blood samples showing signs of 
clotting or hemolysis, as well as samples during which processing problems occurred, were 
excluded from the analysis. White Blood Cells (WBC) populations were identified as neutrophils 
(CD15+/CD193-), eosinophils (SSChi/CD193+), basophils (CD123+/CD203cint/+ or SSClo/CD193+ 
for Fig. 2), monocytes (CD14+/CD3-), B cells (CD19+/CD14-), T cells (CD3+/CD56-) or NK cells 
(CD56+/CD3-). The expression value for each marker was determined as the difference between 
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the geometric mean of the fluorescence intensity of the marker and the geometric mean of the 
matched isotype control (DGeoMean). 
Circulating neutrophil extracellular traps (NETs) quantification 
In order to quantify circulating NETs, DNA-myeloperoxidase (DNA-MPO) complexes were 
measured in serum samples using a capture ELISA described elsewhere (33). Briefly, 96-well 
microtitre plates were coated overnight with 5 µg/mL of rabbit anti-human MPO antibody 
(Millipore®, Billerica, Massachusetts, USA). After blocking with 2% BSA, serum samples were 
added together with a peroxidase-labeled anti-DNA monoclonal antibody (component 2 of the Cell 
Death ELISA kit, Roche). After incubation, the peroxidase substrate was added for 40 min at 37°C. 
Results are expressed as optical absorbance measured at 405 nm in a spectrophotometer. 
Elastase quantification 
Plasma concentrations of human elastase were measured using a commercial ELISA kit (Abcam®, 
Cambridge, UK) according to the manufacturer’s instructions. 
PAF-acetyl hydrolase quantification 
The activity of the enzyme that hydrolyzes and inactivates PAF (PAF-acetyl-hydrolase, PAF-AH) 
inversely correlates with PAF concentrations in human serum(31, 78). Extracellular enzymatic 
activity of PAF-AH was measured in plasma samples using a commercial chromogenic kinetic kit 
(Cayman Chemical, Ann Harbor, Michigan, USA) according to the manufacturer’s instructions. 
Briefly, hydrolysis of a modified substrate (2-thio-PAF) by the PAF-AH contained in plasma 
released a colored product after conjugation with 5,5'-dithiobis-2-nitrobenzoic acid (DTNB). 
Optical absorbance at 405 nm was measured once every minute to obtain 8 time-points. Results 
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are expressed in µmol/min/mL; calculated using the following formula: [PAF-AH (µmol/min/mL) 
= ∆A405 min-1/ 10 mM-1 X 0.225 ml /0.01ml X sample dilution] 
Production and characterization of rocuronium and suxamethonium bioconjugates 
Hapten-protein couplings were performed using active ester derivatives of rocuronium or 
suxamethonium and HSA (Human Serum Albumin) or BSA (Bovine Serum Albumin) as the 
carrier protein.  
- For the rocuronium derivative, a carboxylate function was first introduced by adding succinic 
anhydride to rocuronium bromide in the presence of 4-(dimethylamino)-pyridine in pyridine. After 
stirring overnight at room temperature under argon, the solvent was removed under vacuum. The 
crude compound was purified by reverse-phase flash chromatography (linear gradient 10-80% of 
CH3CN + 0.1% trifluoroacetic acid in H2O + 0.1% trifluoroacetic acid over 60 minutes), resulting 
in a rocuronium derivative with a carboxylic acid at the 3-position of the steroid scaffold (81% 
yield). The compound was characterized by mass spectrometry (Q-Tofmicro™ spectrometer 
(Micromass)) with an electrospray ionization (positive mode) source (Waters, France) 
(C36H57N2O7 calcd. 629.4166, 315.2122; m/z 629.4183 [M+H]+, 315.2085 [M+2H]2+)) and by 
nuclear magnetic resonance analysis (Table S4). 
All quantities of products used in the protocol were calculated relative to the carrier protein. The 
functionalized rocuronium (300 equivalent) was dissolved in 0.1 M MES + 0.5 M NaCl buffer pH 
5.6 and combined with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (1000 equivalent) in the 
presence of N-hydroxysulfosuccinimide (400 equivalent). After 5 minutes stirring at room 
temperature, pH was adjusted to 7.2 with 2 N NaOH. This solution was progressively added to the 
carrier protein dissolved in PBS 1X pH 7.2. After 3 hours of gentle agitation at room temperature 
and extensive dialysis in PBS, the conjugated proteins were obtained at 50% yield.  
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For the suxamethonium derivative, choline chloride was treated as previously reported (79) to 
generate a carboxylated intermediate succinyl-monocholine (93% yield), that was then conjugated 
with the proteins as described above (but at 600 equivalent relative to the carrier protein). The 
resulting conjugates were obtained at 80-85% yield. 
Exact measurement of the concentration of the bioconjugates was achieved by quantitative amino-
acid analysis using a Beckman 6300 analyzer after hydrolysis with 6 N HCl at 110 °C for 20 hours. 
The average density of conjugated rocuronium and suxamethonium derivatives was evaluated by 
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and was found to be 
22±10 and 42±10, respectively, for the HSA conjugates. 
Affinity purification on rocuronium of human polyclonal IgG 
Rocuronium, but not atracurium nor suxamethonium, possesses chemical groups that can be 
targeted for chemical coupling to carrier molecules. Rocuronium was thus the only NMBA that 
could be coupled in vitro as a whole molecule, and we therefore chose to use rocuronium 
conjugates to isolate NMBA-specific IgG. BSA-rocuronium or BSA were coupled overnight to 
CNBr-Activated sepharose 4 Fast Flow (General Electrics®, Buckinghamshire, England) 
according to the manufacturer’s recommendations. BSA sepharose beads were packed in Poly-
Pred Chromatography Columns (Bio-Rad®, Hercules, California, US). Human serum, after 
centrifugation and filtration (0.45 µm), was passed twice through the BSA column. The flow-
through was then incubated overnight with the BSA-rocuronium sepharose beads with agitation. 
Elution was performed with 0.12 M glycine buffer, pH 3.0, eluted antibody fractions were dialyzed 
in 0.1 M Tris buffer pH 8.0 (optimized buffer determined by Dynamic Light Scattering analyses). 
ELISA: Maxisorp 96-well plates were coated with 5µg/mL of carrier proteins, NMBA-conjugated 
carrier protein or allergens, incubated with serial dilutions of human antibodies purified on 
 29 
rocuronium affinity columns, and revealed with HRP-conjugated anti-human IgG secondary 
antibodies (Jackson Immunoresearch) and OPD (Sigma). 
Competition ELISA: 96-well plates were coated with 5-10µg/mL of rocuronium-(20)-HSA. 
Human antibodies purified on rocuronium affinity columns were mixed at 0.9µg/mL with serial 
dilutions (starting at 5mM) of different NMBAs or chemical analogs. Binding of human IgG was 
revealed with HRP-conjugated anti-human IgG secondary antibodies (Jackson Immunoresearch) 
and OPD (Sigma). 
Ex vivo neutrophil activation by [anti-rocuronium IgG - rocuronium HSA bioconjugate] 
immune complexes and drugs used for anaphylaxis treatment. 
Neutrophils from healthy donors were purified using MACSXpress Neutrophil isolation kit 
(Miltenyi Biotech®, Bergisch Gladbach, Germany, which gave a purity routinely over 98%. 
Purified neutrophils were suspended at 1.5x106 cells/mL in Hank’s Balanced Salt Solution (HBSS) 
and 100µL of cells were seeded 96-well plates for stimulation with plate-bound ICs or soluble ICs. 
Plate-bound ICs were prepared by coating 96 well plates with rocuronium-coupled Human Serum 
Albumin (HSA-Roc; 200µg/mL) followed by incubation with patient-derived purified anti-
rocuronium human polyclonal IgG (50µg/mL). Soluble ICs were prepared by mixing HSA-(20)-
Roc (5µg/mL) with anti-rocuronium IgG (100µg/mL). Positive controls were obtained by coating 
with ovalbumin (200µg/mL), followed by rabbit polyclonal anti-ovalbumin antibodies (50µg/mL). 
Negative controls were obtained by coating antigen alone, without further incubation with 
antibodies. Oxidative burst (ROS release) and netosis were measured as previously described (33). 
Briefly, oxidative burst was measured by chemoluminescence at 37°C for 1 h after addition of 
luminol (final concentration 50µM). Results are expressed as peak luminescence value. Netosis 
was measured by cell-free DNA (cf DNA) release using Sytox Green DNA probe 
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(Thermofischer®, final concentration 5µM) at 37°C for 300 min. Results are expressed as 530nm 
fluorescence normalized for baseline and unstimulated controls. Both luminescence and 
fluorescence were read on a microplate reader (TristarTM LB941, Berthold). Neutrophil activation 
was also tested following incubation in solution with epinephrine, ephedrine, methylprednisolone, 
atropine, and various resuscitation fluids, using serial dilutions from drugs vials obtained from an 
intensive care unit. 
Statistical analyses 
Paired comparisons (between patients and matched controls or between inclusion and follow-up 
visits) were performed with a paired Wilcoxon signed rank test. Sub-groups of patients were 
compared with a Mann-Whitney U test. Statistical tests were bilateral and a type I error was fixed 
at 5%. Statistical analyses were performed with GraphPad Prism version 5.0 and 7.0 (GraphPad 
Software Inc., La Jolla, USA), R version 3.0.2 software (R foundation for Statistical Computing, 
Vienna, Austria), and SAS 9.2 (SAS Institute, Cary, North Carolina, USA). 
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Table1. Characteristics of the patients 
 Variable	 Cases	(n=86)	 Controls	(n=86)	 p	Female	gender		 62%	 62%	 1	*	Age	(years)	 57	[40;66]	 58	[42;66]	 0.66	□	Previous	general	anaesthesia		 84%	 87%	 0.66	*	Medication	(ACEI/ARA/BB/CI)		 38%	 29%	 <0.0001	*	History	of	allergy		 	 	 	Drugs		 13%	 13%	 1	*	Latex		 2%	 8%	 0.17	*	Food		 7%	 0%	 0.03	*	Hymenoptera	venom		 3%	 0%	 0.09	*	Pollen/Moth/Animals/Mold	 15%	 13%	 0.83	*	Asthma		 12%	 5%	 0.16	*	Atopy		 21%	 19%	 0.85	*	Type	of	surgery	 	 	 			 Cardio-thoracic,	vascular		 20%	 20%	 1	*			 Maxillo-facial		 8%	 8%	 1	*			 Orthopedic	Neurosurgery		 20%	 20%	 1	*			 Visceral,	Urologic,	Gynecologic	 52%	 52%	 1	*	Scheduled	surgery	 92%	 98%	 0.17	*	Surgery	with	a	context	of	infection	 2.3%	 2.3%	 0.87	*		NMBA	used	during	surgery	 	 	 0.84	*		 Suxamethonium	 56%	 56%	 1	*		 Atracurium	 51%	 51%	 1	*		 Rocuronium	 3%	 3%		 1	*	
Values are expressed as percentages or as median [25th-75th percentile].  
□ Student test. * Exact Fisher test. ACEI: Angiotensin-Converting-Enzyme Inhibitor. ARA: 
Angiotensin II Receptor Antagonist. BB: Beta-blocker. CI: Calcium channel inhibitor. NMBA: 
Neuro-muscular Blocking Agent.  
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Table 2. Clinical signs and therapeutic interventions during acute hypersensitivity reactions, 
according to severity grade.  
 
Clinical/Haemodynamic	signs	 Severe	
(n=43)	
Mild	
(n=43)	
P		 Erythema,	%		 65	 79	 0.2	*		 Tachycardia,	%		 58	 44	 0.3	*		 	 Maximum	HR,	min-1	 130[125;133]	 127[111;136]	 0.3	◊		 Bradycardia,	%		 26	 7	 0.04	*		 	 Minimum	HR,	min-1	 42[40;49]	 52[51;54]	 0.1	◊		 Arrhythmia,	%		 23	 2	 0.007	*		 Arterial	hypotension,	%		 100	 63	 <0.0001	*		 	 Minimum	SAP	value,	mmHg	 50[43;60]	 65[58;73]	 0.01	◊		 Bronchospasm,	%		 37	 28	 0.5	*		 Hypoxemia,	%		 49	 7	 <0.0001	*		 	 Minimum	SpO2,	%	 82[82;88]	 91[90;91]	 0.1	◊		 Hypocapnia,	%		 63	 14	 <0.0001	*		 	 Minimum	etCO2,	mmHg	 18[13;21]	 26[24;29]	 0.002	◊		 Cardiac	arrest,	%		 23	 0	 0.001	*	
Delay	of	resuscitation	 	 	 		
Delay	between	anaesthesia	induction	and	first	signs	of	the	reaction	(min)	 5[5;16]	 5.5[5;10]	 0.6	◊		
Delay	between	first	signs	of	the	reaction	and	treatment	initiation	(min)	 1[0;2]	 0[0;0.75]	 0.008	◊	
Therapeutic	interventions	 	 	 		 Epinephrine	IV	alone,	%	 35	 0	 <0.0001	*		 	 Cumulative	doses	of	epinephrine	(mg)	 2.5[1;6.9]	 NA	 NA		 Norepinephrine	IV	alone,	%	 5	 0	 0.5	*		 	 Cumulative	doses	of	norepinephrine	IV	(mg)	 1.75[1.62;1.87]	 NA	 NA		 Epinephrine	IV	and	Norepinephrine	IV,	%	 12	 0	 0.06	*		 	 Cumulative	doses	of	epinephrine	IV	(mg)	 5[2;5.4]	 NA	 NA		 Ephedrine	and/or	phenylephrine	IV	alone,	%		 0	 44	 <0.0001	*		 Ephedrine	and/or	phenylephrine	IV,	then	epinephrine	and/or	norepinephrine	
IV,	%		
49	 2	 <0.0001	*		 	 Cumulative	doses	of	epinephrine	IV	(mg)	 0.6[0.3;4.1]	 0.1	 NA		 Atropine	IV,	%	 12	 5	 0.4	*		 	 Cumulative	doses	of	atropine	IV	(mg)	 1[1;1]	 1[1;1]	 NA		 Beta2-adrenergic	agonist	IV/inhaled,	%		 14	 12	 1	*		 Glucocorticoids,	%		 23	 23	 1	*		 Histamine	receptor	antagonists,	%		 0	 2	 1	*		 Fluid	resuscitation	with	crystalloids,	%		 70	 42	 0.02	*		 	 Cumulative	volume	of	crystalloids	(l)	 1[1;2]	 0.87[0.5;1.37]	 0.03	◊		 Fluid	resuscitation	with	colloids,	%		 83	 9	 0.008	*		 	 Cumulative	volume	of	colloids	(l)	 0.5[0.5;1]	 0.65[0.5;0.85]	 0.8	◊	
Evolution	 	 	 		 Surgery	cancelled,	%	 81	 19	 <0.0001	*		 Admission	to	ICU,	%	 76	 26	 <0.0001	*	
 
Values are expressed as percentages or as median [25th-75th percentile] when appropriate. The 
numbers of observations and missing values varied according to the numeric value analysed: 
maximum HR (43/17), minimum HR (14/6), minimum PAS (70/21), minimum SpO2 (24/9), 
minimum etCO2 (33/7).  
etCO2: end-tidal CO2. HR: Heat Rate. ICU: Intensive Care Unit. IV: Intravenous. NA: Non-
available. ND: Not-done. SAP: Systolic arterial Pressure. SpO2: Photoplethysmographic oxygen 
saturation. ◊ Mann & Whitney test. * Exact Fisher test. 
  
 43 
FIGURES 
 
 
 
Figure 1: Anti-NMBA specific antibodies concentrations are elevated in severe AHR 
(a-d) Schematic representation of (a) morphine (QAM), (b) suxamethonium, (c) atracurium and 
(c) rocuronium). (e,f) Measurements of (e) IgE and (f) IgG against quaternary ammonium 
morphine antigen (QAM) in patients presenting with mild AHR (n=43), severe AHR (n=43) and 
matched controls (n=86). Wilcoxon signed rank test: ****P<0.0001, **P<0.01, *P<0.05. Mann-
Whitney test: ####P<0.0001, ###P<0.001. (d,e) Results are represented as boxplots; whiskers 
indicate the 10th and 90th percentiles. (g) Plotting of individual data of anti-QAM IgE and IgG 
concentrations for controls (orange triangles) and patients (blue diamonds). Inset: correlation plot 
including only patients and controls with anti-QAM IgE>0.3kU/L. Spearman-correlation: 
***P<0.001. 
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Figure 2 : Modulation of IgE and IgG receptor expression on myeloid cells during AHR 
(a,b) FcεRI, (c,d) CD64 (FcγRI), (e-h) CD32A (FcγRIIA), (i,j) CD32B (FcγRIIB), and (k,l) CD16 
(FcγRIII) expression on circulating basophils (a,g,i), eosinophils (b,f), neutrophils (c,e,k) and 
monocytes (d,h,j,l) in the blood from patients 30 minutes after onset of AHR, during the follow-
up visit (V2) or from matched controls. Values represent the delta geometric mean (ΔGeoMean) 
between specific staining and corresponding isotype or fluorescence-minus-one control. Wilcoxon 
signed rank test: ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05. Mann-Whitney test: 
####P<0.0001, ##P<0.01, #P<0.1. All boxplots whiskers represent 5th and 95th percentiles. 
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Figure 3: Circulating neutrophils are activated during AHR. 
(a-c) Surface expression on circulating neutrophils of activation markers (a) CD11b, (b) CD18 and 
(c) CD66b expressed as geometric mean of fluorescence intensity after subtraction of isotype 
control. (d) Neutrophil elastase in the plasma of patients 30 minutes after AHR occurrence in mild 
(n=37) or severe (n=32) AHR patients, at their follow-up visit (V2, n=69) or in healthy controls 
(n=30). (e) Circulating NETs measured as DNA-MPO complexes in the serum of patients 30 
minutes after AHR occurrence in mild (n=43) or severe (n=43) AHR patients, at their follow-up 
visit (V2, n=86) or in matched controls (n=86). (f) Activity of PAF-AH in the plasma of patients 
30 minutes after AHR occurrence in mild (n=42) or severe (n=42) AHR patients, or of healthy 
controls (n=33). Wilcoxon signed rank test: ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05. 
Mann-Whitney test: ####P<0.0001, ###P<0.001, ##P<0.01. All boxplots whiskers represent 10th 
and 90th percentiles. 
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Figure 4: Evidence of an IgG-neutrophil-PAF pathway in the presence or absence of IgE-
mediated anaphylaxis markers 
Evidence for IgE-dependent anaphylaxis was classified as “absent” (n=27), “equivocal” (n=19) or 
“strong” (n=40) for each patient of the NASA cohort. Data from Figures 1-3 were reanalyzed 
based on these criteria, and (a) FcεRI expression on basophils, (b) anti-NMBA IgG, or (c) CD32B 
expression on basophils, (d) CD32A expression on monocytes, (e) CD32A or (f) CD16 expression 
on neutrophils, circulating (g) neutrophil elastase or (h) NETs (DNA-MPO complexes), (i) CD11b, 
(j) CD18, (k) CD66b expression on neutrophils and (i) plasma PAF-AH activity were compared 
between controls and patients with “absent”, “equivocal” or “strong” evidence for IgE-dependent 
anaphylaxis. Wilcoxon signed rank test: ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05. Mann-
Whitney test: ####P<0.0001, ###P<0.001, ##P<0.01. All boxplots whiskers represent 10th and 
90th percentiles.  
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Figure 5: [NMBA - anti-NMBA IgG] complexes activate neutrophils ex vivo 
 (a) Anti-rocuronium ELISA revealing 4 patients with high rocuronium-specific IgG antibody 
(colored lines) in the cohort (all other patients are indicated by grey lines). (b) Specificity of 
purified anti-rocuronium IgG measured by ELISA against indicated protein antigens and their 
morphine- (Morph), suxamethonium (Suxa)-, rocuronium (Roc)-derivatives or against common 
allergens: amoxicillin, peanut extract, Bet v 1 (the major birch pollen antigen, Betula verrucosa) 
and ovalbumin. One of two independent experiments (c) Flow cytometric analysis of the binding 
of [anti-rocuronium IgG + rocuronium-HSA] immune complexes to cell transfectants expressing 
human CD16A/FcγRIIIA variant V176 (blue line), compared to rocuronium-HSA alone (black 
line), and unstained cells (grey shaded histogram), one of three independent experiments. (d,e) 
Fluorescent-based measurement of (d) ROS or (e) cell-free DNA (NETs) released by purified 
neutrophils from healthy donors (n=4), either left untreated (media), or incubated with control ICs 
(OVA IC), rocuronium-HSA (HSA-Roc) or [anti-rocuronium IgG + rocuronium-HSA] complexes 
(Roc IC).  Error bars represent standard deviation. *P<0.01, Mann-Whitney test. 
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